Safety of subcutaneous immunotherapy with inhalant allergen extracts: a single-center 30-year experience from Turkey

Basit Öğe Kaydı
dc.contributor.authorKartal, Ozgur
dc.contributor.authorGulec, Mustafa
dc.contributor.authorCaliskaner, Zafer
dc.contributor.authorMusabak, Ugur
dc.contributor.authorSener, Osman
dc.date.accessioned2024-02-23T14:34:36Z
dc.date.available2024-02-23T14:34:36Z
dc.date.issued2015
dc.departmentNEÜen_US
dc.description.abstractContext: Although subcutaneous allergen immunotherapy (SCIT) is effective in allergic rhinitis (AR) and asthma, it carries a risk of local and systemic adverse reactions. Objective: The aim of this study was to evaluate the rates and clinical characteristics of local and systemic reactions (LR and SR), and to identify their relation of demographic features, allergen extracts and diagnosis. Materials and methods: This study analyzed the administration of SCIT from 1983 to 2013; involving 1816 patients affected by allergic asthma and/or AR. Results: The rates of SR from SCIT were 0.078% per injection and 9% per patient. According to the World Allergy Organization 2010 grading system, 91 grade 1 reactions (44%), 67 grade 2 reactions (32.3%), 33 grade 3 reactions (16%) and 16 grade 4 reactions (7.7%) were seen. There was no fatal outcome from any of the SRs. Risk factors for a SR included: aluminium-adsorbed extract, pollen-containing vaccines, large LR and recurrent (>= 2) LRs. The total LR rates were 0.062% per injection and 5.2% per patient; the small LR rates were 0.027% per injection and 2.3% per patient, and the large LR rate were 0.035% per injection and 2.9% per patient. Female gender, depot extracts, calcium phosphate-adsorbed extract and pollen vaccines were identified as risk factors for LR. Conclusion: The analysis of our data over a 30-year period confirmed that SCIT with inhalant allergens conducted strictly according to the standard protocols and when administrated by experienced staff is a safe method of treatment with only a few side-effects.en_US
dc.identifier.doi10.3109/08923973.2015.1027918
dc.identifier.endpage286en_US
dc.identifier.issn0892-3973
dc.identifier.issn1532-2513
dc.identifier.issue3en_US
dc.identifier.pmid25858053en_US
dc.identifier.scopus2-s2.0-84931045934en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage280en_US
dc.identifier.urihttps://doi.org/10.3109/08923973.2015.1027918
dc.identifier.urihttps://hdl.handle.net/20.500.12452/15664
dc.identifier.volume37en_US
dc.identifier.wosWOS:000359990100009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofImmunopharmacology And Immunotoxicologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectInhalant Allergensen_US
dc.subjectLocal Reactionen_US
dc.subjectRisk Factorsen_US
dc.subjectSubcutaneous Allergen Immunotherapyen_US
dc.subjectSystemic Reactionen_US
dc.titleSafety of subcutaneous immunotherapy with inhalant allergen extracts: a single-center 30-year experience from Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu